Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk (NYSE: NVO )'s Wegovy or Eli Lilly (NYSE: LLY )'s Zepbound, ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market.

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

Scholars discuss the regulatory landscape surrounding GLP-1 drugs and dietary supplements.

The yield has risen 73.6 basis points over the past seven weeks, according to Dow Jones Market Data. On Friday, traders were ...

A registered dietitian reveals nine food that work like weight-loss drugs, helping to curb cravings and suppress your ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...